Personal CFO Solutions LLC Takes Position in Exact Sciences Co. (NASDAQ:EXAS)

Personal CFO Solutions LLC purchased a new position in shares of Exact Sciences Co. (NASDAQ:EXAS) in the 2nd quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission. The institutional investor purchased 2,411 shares of the medical research company’s stock, valued at approximately $226,000.

Other hedge funds have also recently modified their holdings of the company. Park Place Capital Corp increased its holdings in shares of Exact Sciences by 189.2% during the 1st quarter. Park Place Capital Corp now owns 376 shares of the medical research company’s stock worth $25,000 after buying an additional 246 shares during the last quarter. True Wealth Design LLC acquired a new stake in shares of Exact Sciences during the 4th quarter worth approximately $30,000. TCI Wealth Advisors Inc. increased its holdings in shares of Exact Sciences by 15,466.7% during the 1st quarter. TCI Wealth Advisors Inc. now owns 467 shares of the medical research company’s stock worth $32,000 after buying an additional 464 shares during the last quarter. Ameritas Advisory Services LLC acquired a new stake in shares of Exact Sciences during the 1st quarter worth approximately $32,000. Finally, Money Concepts Capital Corp acquired a new stake in shares of Exact Sciences during the 4th quarter worth approximately $36,000. Institutional investors and hedge funds own 89.13% of the company’s stock.

Analyst Upgrades and Downgrades

A number of analysts have recently issued reports on EXAS shares. The Goldman Sachs Group cut their price target on shares of Exact Sciences from $100.00 to $90.00 and set a “buy” rating for the company in a report on Friday, November 3rd. Bank of America increased their price objective on shares of Exact Sciences from $105.00 to $110.00 in a research report on Wednesday, August 2nd. Jefferies Financial Group increased their price objective on shares of Exact Sciences from $100.00 to $110.00 and gave the stock a “buy” rating in a research report on Thursday, August 3rd. StockNews.com assumed coverage on shares of Exact Sciences in a research report on Thursday, October 5th. They set a “hold” rating for the company. Finally, Credit Suisse Group increased their price objective on shares of Exact Sciences from $75.00 to $90.00 and gave the stock a “neutral” rating in a research report on Wednesday, August 2nd. Five investment analysts have rated the stock with a hold rating and twelve have assigned a buy rating to the company’s stock. According to MarketBeat.com, the stock has an average rating of “Moderate Buy” and an average target price of $96.56.

Insider Buying and Selling at Exact Sciences

In other news, insider Everett Cunningham sold 13,007 shares of Exact Sciences stock in a transaction on Thursday, October 12th. The shares were sold at an average price of $66.49, for a total transaction of $864,835.43. Following the completion of the sale, the insider now directly owns 37,909 shares of the company’s stock, valued at approximately $2,520,569.41. The transaction was disclosed in a filing with the SEC, which is available through the SEC website. 1.30% of the stock is currently owned by corporate insiders.

Exact Sciences Stock Performance

Shares of EXAS stock opened at $67.29 on Tuesday. The company has a quick ratio of 2.13, a current ratio of 2.41 and a debt-to-equity ratio of 0.74. Exact Sciences Co. has a 52 week low of $40.73 and a 52 week high of $100.77. The stock has a market capitalization of $12.17 billion, a PE ratio of -42.32 and a beta of 1.46. The firm has a 50 day moving average of $66.20 and a two-hundred day moving average of $79.81.

Exact Sciences Profile

Exact Sciences Corporation provides cancer screening and diagnostic test products in the United States and internationally. The company offers Cologuard, a non-invasive stool-based DNA screening test to detect DNA and hemoglobin biomarkers associated with colorectal cancer and pre-cancer. It also provides Oncotype DX Breast Recurrence Score Test; Oncotype DX Breast DCIS Score Test; Oncotype DX Colon Recurrence Score Test; OncoExTra Test for tumor profiling for patients with advanced, metastatic, refractory, relapsed, or recurrent cancer; and Covid-19 testing services.